Ryosuke Shimizu

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Respiratory Syndrome Coronavirus

Prognostic Factors

Patient Reported

Top Venues

CPT: pharmacometrics & systems pharmacology

Antimicrobial agents and chemotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Daichi Yamaguchi, Ryosuke Shimizu, Ryuji Kubota
Development of a SARS-CoV-2 viral dynamic model for patients with COVID-19 based on the amount of viral RNA and viral titer. CPT: pharmacometrics & systems pharmacology 13 (8) (2024)
Daichi Yamaguchi, Ryosuke Shimizu, Ryuji Kubota
Development of a SARS-CoV-2 viral dynamic model for patients with COVID-19 based on the amount of viral RNA and viral titer. CPT: pharmacometrics & systems pharmacology 13 (8) (2024)
Daichi Yamaguchi, Ryosuke Shimizu, Ryuji Kubota
Development of a SARS-CoV-2 viral dynamic model for patients with COVID-19 based on the amount of viral RNA and viral titer. CPT: pharmacometrics & systems pharmacology (2024)
Daichi Yamaguchi, Ryosuke Shimizu, Ryuji Kubota
Development of a SARS-CoV-2 viral dynamic model for patients with COVID-19 based on the amount of viral RNA and viral titer. CPT: pharmacometrics & systems pharmacology 13 (8) (2024)
Ryosuke Shimizu, Takuhiro Sonoyama, Takahiro Fukuhara, Aya Kuwata, Yumiko Matsuo, Ryuji Kubota
Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults. Antimicrobial agents and chemotherapy 66 (10) (2022)